50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   272.99 (-2.48%)
AAPL   143.98 (-3.91%)
MSFT   236.53 (-1.88%)
META   138.09 (-2.49%)
GOOGL   97.45 (-2.60%)
AMZN   115.03 (-2.53%)
TSLA   276.08 (-4.08%)
NVDA   122.72 (-3.64%)
NIO   16.47 (-4.96%)
BABA   78.18 (-3.47%)
AMD   65.42 (-4.30%)
T   15.57 (-1.64%)
MU   49.57 (-2.80%)
CGC   2.88 (-5.26%)
F   11.56 (-5.09%)
GE   62.70 (-2.73%)
DIS   97.46 (-1.95%)
AMC   7.34 (-4.30%)
PYPL   89.52 (-1.76%)
PFE   44.21 (-0.50%)
NFLX   241.79 (-1.39%)
QQQ   272.99 (-2.48%)
AAPL   143.98 (-3.91%)
MSFT   236.53 (-1.88%)
META   138.09 (-2.49%)
GOOGL   97.45 (-2.60%)
AMZN   115.03 (-2.53%)
TSLA   276.08 (-4.08%)
NVDA   122.72 (-3.64%)
NIO   16.47 (-4.96%)
BABA   78.18 (-3.47%)
AMD   65.42 (-4.30%)
T   15.57 (-1.64%)
MU   49.57 (-2.80%)
CGC   2.88 (-5.26%)
F   11.56 (-5.09%)
GE   62.70 (-2.73%)
DIS   97.46 (-1.95%)
AMC   7.34 (-4.30%)
PYPL   89.52 (-1.76%)
PFE   44.21 (-0.50%)
NFLX   241.79 (-1.39%)
QQQ   272.99 (-2.48%)
AAPL   143.98 (-3.91%)
MSFT   236.53 (-1.88%)
META   138.09 (-2.49%)
GOOGL   97.45 (-2.60%)
AMZN   115.03 (-2.53%)
TSLA   276.08 (-4.08%)
NVDA   122.72 (-3.64%)
NIO   16.47 (-4.96%)
BABA   78.18 (-3.47%)
AMD   65.42 (-4.30%)
T   15.57 (-1.64%)
MU   49.57 (-2.80%)
CGC   2.88 (-5.26%)
F   11.56 (-5.09%)
GE   62.70 (-2.73%)
DIS   97.46 (-1.95%)
AMC   7.34 (-4.30%)
PYPL   89.52 (-1.76%)
PFE   44.21 (-0.50%)
NFLX   241.79 (-1.39%)
QQQ   272.99 (-2.48%)
AAPL   143.98 (-3.91%)
MSFT   236.53 (-1.88%)
META   138.09 (-2.49%)
GOOGL   97.45 (-2.60%)
AMZN   115.03 (-2.53%)
TSLA   276.08 (-4.08%)
NVDA   122.72 (-3.64%)
NIO   16.47 (-4.96%)
BABA   78.18 (-3.47%)
AMD   65.42 (-4.30%)
T   15.57 (-1.64%)
MU   49.57 (-2.80%)
CGC   2.88 (-5.26%)
F   11.56 (-5.09%)
GE   62.70 (-2.73%)
DIS   97.46 (-1.95%)
AMC   7.34 (-4.30%)
PYPL   89.52 (-1.76%)
PFE   44.21 (-0.50%)
NFLX   241.79 (-1.39%)
NASDAQ:BIOC

Biocept - BIOC Stock Forecast, Price & News

$0.95
+0.05 (+5.43%)
(As of 09/29/2022 09:41 AM ET)
Add
Compare
Today's Range
$0.95
$0.95
50-Day Range
$0.75
$1.20
52-Week Range
$0.72
$4.40
Volume
33 shs
Average Volume
49,704 shs
Market Capitalization
$16.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Biocept MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
344.4% Upside
$4.00 Price Target
Short Interest
Healthy
0.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Biocept in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.66) to ($1.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

442nd out of 1,096 stocks

Medical Laboratories Industry

12th out of 30 stocks

BIOC stock logo

About Biocept (NASDAQ:BIOC) Stock

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Stock News Headlines

Biocept (NASDAQ:BIOC) Now Covered by Analysts at StockNews.com
Biocept Appoints RSM as Independent Auditor
Form 8-K BIOCEPT INC For: Jun 10 - StreetInsider.com
See More Headlines
Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Company Calendar

Last Earnings
11/15/2021
Today
9/29/2022
Next Earnings (Estimated)
10/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOC
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+321.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-2,820,000.00
Pretax Margin
-12.72%

Debt

Sales & Book Value

Annual Sales
$61.25 million
Book Value
$2.23 per share

Miscellaneous

Free Float
16,688,000
Market Cap
$16.06 million
Optionable
Optionable
Beta
0.78

Key Executives

  • Mr. Samuel D. Riccitelli (Age 63)
    Interim Pres, CEO & Chairman
    Comp: $67.24k
  • Mr. Antonino Morales (Age 66)
    Interim CFO & Director
    Comp: $20.76k
  • Dr. Michael C. Dugan M.D. (Age 59)
    Sr. VP, Chief Medical Officer & Medical Director
    Comp: $413.31k
  • Dr. Soon Kap Hahn Ph.D.
    Founder
  • Dr. Philippe J. Marchand Ph.D. (Age 59)
    Chief Operating Officer
  • Mr. Pavel Tsinberg
    Director of Technology Devel.
  • Mr. Darrell Taylor Esq. (Age 57)
    Sr. VP, Chief Legal Officer & Chief Compliance Officer
  • Mr. David S. Moskowitz R.Ph.
    MBA, VP of Strategy & Corp. Communications
  • Mr. Michael Terry (Age 67)
    Sr. VP of Corp. Devel.
  • Antonio Paternostro
    VP of Sales













BIOC Stock - Frequently Asked Questions

Should I buy or sell Biocept stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOC shares.
View BIOC analyst ratings
or view top-rated stocks.

What is Biocept's stock price forecast for 2022?

2 Wall Street analysts have issued 12-month price objectives for Biocept's shares. Their BIOC share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 344.4% from the stock's current price.
View analysts price targets for BIOC
or view top-rated stocks among Wall Street analysts.

How have BIOC shares performed in 2022?

Biocept's stock was trading at $3.62 on January 1st, 2022. Since then, BIOC stock has decreased by 75.1% and is now trading at $0.9001.
View the best growth stocks for 2022 here
.

When is Biocept's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 3rd 2022.
View our BIOC earnings forecast
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings results on Monday, November, 15th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.06. The medical research company earned $17.47 million during the quarter, compared to the consensus estimate of $16.87 million. Biocept had a negative trailing twelve-month return on equity of 19.99% and a negative net margin of 11.26%. During the same quarter in the prior year, the firm posted ($0.43) earnings per share.

When did Biocept's stock split?

Shares of Biocept reverse split before market open on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Michael Nall's approval rating as Biocept's CEO?

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.04%), Millennium Management LLC (0.61%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David F Hale and David F Hale.
View institutional ownership trends
.

How do I buy shares of Biocept?

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.90.

How much money does Biocept make?

Biocept (NASDAQ:BIOC) has a market capitalization of $15.23 million and generates $61.25 million in revenue each year. The medical research company earns $-2,820,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

How many employees does Biocept have?

The company employs 104 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.

This page (NASDAQ:BIOC) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.